China clinical trials are attracting international drugmakers seeking faster patient recruitment and lower costs, while raising questions about safety oversight and transparency. China accounted for 45% of new clinical trials for innovative medicines in 2025, according to pharmaceutical data provider Norstella. Its share stood below 5% in 2008. Meanwhile, McKinsey estimates that Phase 1 costs per patient in China are…